Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New laser could ease glaucoma without drops

NCT ID NCT05902871

Disease control Sponsor: BelkinVision Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 18, 2026 · Updated 3 times

Summary

This study tests a new laser procedure called Direct Selective Laser Trabeculoplasty (DSLT) in 40 ethnic Chinese patients with glaucoma or high eye pressure. The laser aims to improve fluid drainage in the eye and reduce pressure. Researchers will check if the treatment is safe and effective over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Direct Selective Laser Trabeculoplasty (DSLT) using the Eagle device
What this could lead to
If successful, this could offer a safe, quick laser treatment to lower eye pressure and help manage glaucoma without daily eye drops.
What could go wrong
This is a small, early-stage study with only 40 participants. Results may not apply to all glaucoma patients, and long-term safety and effectiveness are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Mar 2024

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Chinese ethnicity with corrected visual acuity greater than 6/18 in both eyes. * Diagnosed with mild to moderate primary open angle glaucoma, ocular hypertension, or normal tension open angle glaucoma. * Willing and able to participate in a 12-month study, comply with the study procedures, and adhere to the follow-up schedule. * Capable of giving informed consent. * Other protocol-specified inclusion criteria may apply. Key Exclusion Criteria: * Eye conditions as specified in the protocol. * Use of medications as specified in the protocol. * Unable to provide a reliable visual field test. * Women who are pregnant or may become pregnant during the study. * Prior surgery in the study eye. * In a vision-dependent profession such as pilot or commercial driver. * Other protocol-specified exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Normal tension glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glaucoma low tension glaucoma ocular hypertension open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Normal tension glaucoma Ocular hypertension Primary open-angle glaucoma

Contacts and locations

Locations

  • C-Mer Eye Clinic

    Hong Kong, China

  • SERI

    Singapore, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.